Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

Sima Jeha(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital), Zhaohui Gu(City of Hope), Susana C. Raimondi(St. Jude Children's Research Hospital), James R. Downing(St. Jude Children's Research Hospital), Tanja A. Grüber(Palo Alto University), Chunxu Qu(St. Jude Children's Research Hospital), Elaine Coustan‐Smith(St. Jude Children's Research Hospital), Kathryn G. Roberts(St. Jude Children's Research Hospital), Samuel W. Brady(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Dario Campana(National University of Singapore), Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), John Choi(Children's of Alabama), Raul C. Ribeiro(St. Jude Children's Research Hospital), Cheng Cheng(St. Jude Children's Research Hospital), Williams E. Evans(St. Jude Children's Research Hospital), Seth E. Karol(St. Jude Children's Research Hospital), Deqing Pei(St. Jude Children's Research Hospital), Mary V. Relling(St. Jude Children's Research Hospital)
Blood Cancer Discovery
April 10, 2021
Cited by 162


Related Papers